Development of KCC2 therapeutics to treat neurological disorders

Shilpa D. Kadam, Shane V. Hegarty · 2024

Read Development of KCC2 therapeutics to treat neurological disorders by Shilpa D. Kadam, Shane V. Hegarty (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11666659.txt.

Description

Kadam and Hegarty review in 2024 efforts to build drugs that raise the activity of KCC2, a chloride pump found only in central nerve cells. The pump sets the chloride gradient that lets inhibition work in the brain. Its failure is a shared pathology across epilepsy, chronic pain, and many brain disorders.

When the pump underperforms, inhibitory signals can turn excitatory, and circuits overfire. The gene behind the pump is now a validated target for epilepsy and autism spectrum conditions. Mutations also link to mood disorders. Drugs that lift pump activity hold broad promise in their account, partly since standard drugs lean on the very inhibition this pump enables.

Catalog record

CREATORShilpa D. Kadam, Shane V. Hegarty
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE29 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11666659

Browse the full library · About the Tower of Babel